Worldwide Market for the Clinical Management of Obesity, 2007-2015 – Aarkstore Enterprise

The report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient population in obesity, detailing their incidence in the U.S., Europe, and Rest of World, and the clinical practices in obesity management encompassing surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Europe and Rest of World. The report profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

For more information, kindly visit :
http://www.aarkstore.com/reports/Worldwide-Market-for-the-Clinical-Management-of-Obesity-2007-2015-2064.html

Welcome to Aarkstore Market Research Aggregation

We specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether you’re looking for new product trends or competitive analysis of a new or existing market, Aarkstore.com has the best resource offerings and the expertise to make sure you get the right product every time. 
 
http://www.aarkstore.com

Research Report on Global and Chinese Blood Product Industry, 2009

The blood product industry is stemmed and developed from the blood transfusion, belonging to the conceptual category of biological products. The blood products, extracted the plasma proteins and factor concentrates from the blood, are the precious human biological products with irreplaceable prevention functions to many diseases. So far, there is no qualified man-made substitute.

In 2008, the market scale of global blood products were 12 billion USD, up by about 10% of 2007. The giants, CSL Behring, Talecris Biotherapeutics Inc, Grifols, S.A., Baxter International Inc, Octapharma AG and etc, occupied the major market shares. The market concentration of the global blood product industry was improved. After the merger of Bayer by Talecris Biotherapeutics Inc, CSL Behring merged Talecris Biotherapeutics Inc with 3.1 billion USD.

In 2008, the market scale of Chinese blood products was less than 1 billion USD. Shanghai RAAS Blood Products Co., Ltd, Hualan Biological Engineering Inc and Beijing Tiantan Biological Products Co., Ltd were the leaders of Chinese blood product industry. The scales of Chinese domestic blood product enterprises were all very small. The major factors affecting the development of the enterprises were capitals, technologies and materials and so on. The competitiveness of Chinese blood product enterprises mainly showed in the plasma volumes in operation, production lines and brand construction. The plasma volumes in operation not only represented the scale effect but also reflected the enterprises` control abilities of the blood resources; the production lines represented not only the technological levels of the blood product enterprises but also means single product costs undertook by more products. The brand construction represented that the price would not be the only standard to determine the sales volumes because of the special safety requirements of the blood products. The famous enterprises could get comparatively high gross profit rate in the process of competition. In 2008, the gross profits of Chinese blood products were between 20 to 60 percent.

In 2008, the yields of Chinese blood products were decreased compared with last year. However, because of the growth in the average sale price of Chinese blood products, the total sales revenues were increased compared with last year.

The major reason for the yield decline of Chinese blood products is the bottleneck in the raw materials, the policy elements leading to the insufficient collections of the Source Plasma. Out of the consideration for the safety, Chinese government lists injection, biological products and special medicines as the high risky supervised products, blood products and vaccines as the key highly risky products. Since 1st July, 2008, Chinese government carried out the inspection period systems to the source plasma before the production of blood products, that is to lay aside the collected qualified source plasma for 90 days, then make a serological and virology inspection of the donatorfs plasma sample, if qualified, the source plasma could be used into the production of blood products. This measure strengthened the safety of the blood products, but leading to the reduction in the plasma collections.

The blood products can not meet the demands in Chinese market. It is estimated that the homophile numbers in China are about 80 to 100 thousand, four fifths of which are short of ‡[ factor and only less than 10% of which are received the formal treatments.

Out of consideration for the prevention of blood diseases, such as AIDS, Chinese government limited the imports of blood products abroad from 1986. According to the present situation of the demands of the blood products exceeding the supplies and the pursuit of the blood products, the limitations for the blood products will loosen. In May of 2008, Chinese government announced that the import temporary tariff was adjusted from 3% to zone from 1st June, 2008 to 3rd December, 2008, including antiserum, human vaccines, culture organism and the similarities of the blood albumin and human vaccines.

The international blood product giants, such as CSL Behring and Baxter International Inc. have already distributed in China and developed fast.

With the development of Chinese blood product industry, the concentration of Chinese blood product industry is also improved. The competitions among the blood product enterprises are mainly the comprehensive strength competitions, such as the researches on the new products, the marketing promotions, the quality and safety of the products and the control ability of the blood raw materials. Meanwhile, the mergers and acquisitions among the enterprises went on all the time. In 2008, Beijing Tiantan Biological Products Co., Ltd had become the largest enterprises of blood products by merging Chengdu Rongsheng Biological Products Co., Ltd

As far as the oversea blood product enterprises are concerned, there exists huge market potential in Chinese blood product industry. On the one hand, they can obtain rich profits by exporting blood products to China. On the other hand, they can set up production bases in China by finding out the merger and acquisition opportunities among Chinese blood product enterprises.

The author wrote this report by the interviews of the patients and enterprises and the profound investigation into Chinese blood product industry.

For more information, kindly visit :
http://www.aarkstore.com/reports/Research-Report-on-Global-and-Chinese-Blood-Product-Industry-2009-12833.html

Research Report on China’s foot-and-mouth disease Vaccine (FMD Vaccine) Industry, 2009

Foot-and-mouth disease was the first animal virus people recognized. People had struggled with it for more than one hundred years. Besides several countries with natural quarantine conditions, foot-and-mouth disease still out broke and spread in many countries. Since the reform and open up, the animal husbandry has developed fast in China. However, because of the backward cultivation in the rural, the unsoundness of animal epidemic prevention systems and the outbreaks of foot-and-mouth disease in the neighboring countries, the foot-and-mouth disease greatly affected Chinese animal husbandry.

There are totally seven kinds of foot-and-mouth diseases, including A, O, C, Asia I, and Africa I, II, III etc, which mainly infect the artiodactyls, such as cattle, sheep, pig and camel etc. In 2004, Asia foot-and-mouth disease I spread into China. During 2004-2008, the foot-and-mouth disease in China all belonged to Asia foot-and-mouth disease I. Because of the fast spread speed, highly infected, Chinese animal husbandry was greatly influenced. The World Organization for Animal Health listed the disease as the disease A. China also strengthened the prevention.

In accordance with Law on Animal Disease Prevention of the People’s Republic of China issued by Chinese government in July, 1997, Chinese government took compulsory immunization on the foot-and-mouth disease, namely, the government purchased the foot-and-mouth disease vaccines and handed them out free to the animal raisers. In 2008, the sales volumes of the foot-and-mouth disease vaccines were about 4.2 million liters with the market scales of 1.9 billion Yuan (270 million USD). It is predicted that the data will be held the line in 2009 and 2010.

The production models of Chinese animal vaccines are: the occurrence of epidemics, the public bidding by local government, the production of enterprises and the hand-out by local government. Because the government undertakes the major responsibilities of epidemic prevention, the government purchase are the driving forces of the development in Chinese animal vaccine industry.

During 2007 to 2008, the outbreaks of Asia foot-and-mouth disease I turned down successively, only about three in the whole year of 2008. But at the beginning of 2009, the foot-and-mouth disease broke out frequently. On 13th January, 2009, the occurrence of cattle foot-and-mouth disease A in Wuhan of Hubei province was the first case of foot-and-mouth disease A in China. Foot-and-mouth disease A mainly lies in the Asia, South Africa and Middle East. In recent years, the neighboring countries of China took place the foot-and-mouth disease for several times. On 14th, January, Asia foot-and-mouth disease I took place in Xinjiang Aksu Region. In February, 2009, there happened a foot-and-mouth disease in Shanghai.
@
The foot-and-mouth disease probably leads to serious results, which has already attracted highly social attentions. In the beginning of 2009, foot-and-mouth disease occurred frequently in China, raising the demands for vaccines in a short time. From a long run, with the development of animal husbandry and the worries about the result of foot-and-mouth disease, the demands for the vaccines will also grow and the related enterprises will face a prosperous development.

Animal vaccines are typically featured as event movement. When major epidemics occur, the government will accelerate their purchases of vaccines. Therefore, the occurrence of epidemics is bad news for animal husbandry but development opportunities for animal vaccine industry (the increase of purchase types and quantities). In the beginning of 2009, the epidemics of foot-and-mouth disease A stimulated the vaccine purchases.

More following information can be obtained in this report:
- Outbreaks of the foot-and-mouth disease in China, 2007-2009
- Amounts on hand and sales amount of the cattle, sheep and pig etc in recent years in China
- Scales of Chinese foot-and-mouth disease vaccine market
- Major enterprises of Chinese foot-and-mouth disease vaccines
- Investment opportunities of Chinese foot-and-mouth disease vaccine market
- Development trends of Chinese foot-and-mouth disease vaccines

For more information, kindly visit :
http://www.aarkstore.com/reports/Research-Report-on-China-s-foot-and-mouth-disease-Vaccine-FMD-Vaccine-Industry-2009-12828.html

Surgical Assist, Campus, Personal Services, and Pharmaceutical Robot Market Shares, Market Strategies, and Market Forecasts, 2008-2014

During a robot assisted surgical procedure, the patient-side cart is positioned next to the operating table with the electromechanical arms arranged to provide access to the initial ports selected by the surgeon. Metal tubes attached to the arms are inserted through the ports, and the cutting and visualization instruments are introduced through the tubes into the patient’s body.

Next generation intuitive surgery is implemented with robotic devices. The robotic surgical systems are designed to provide the surgeon with the intuitive control, range of motion, fine tissue manipulation capability, and 3-D vision characteristic of open surgery. Systems work by simultaneously allowing the surgeon to work through the small ports of MIS. All this is accomplished in an intuitive manner, in the same way that the movements of a surgeon’s hands in open surgery are entirely intuitive.

The surgeon performs the procedure while sitting at a console, manipulating the instrument controls and viewing the operation through a vision system. When a surgeon needs to change an instrument the instrument is withdrawn from the surgical field using the controls at the console. This is done many times during an operation.

People are making existing MIS procedures easier, safer and more cost-effective than the alternative methods. The strategy is to broaden the number of procedures performed using a robotic surgical system and to educate surgeons, hospitals and patients as to the benefits of robotic surgery. Key elements of strategy include a focus on key procedures. Procedure marketing efforts are primarily focused within four surgical specialties: urologic surgery, gynecologic surgery, cardiothoracic surgery, and general surgery.

Systems pose a challenge to be relevant and individualized to the special needs of each user. Social behavior plays a fundamental role in assisting all people, including people with special needs. The robot’s physical embodiment, its physical presence and appearance, and its shared context with the user, are fundamental for creating a time-extended engaging relationship with the user.

An adaptive, reliable and user-friendly hands-off robot needs to provide an engaging and motivating customized therapy protocol to participants in school, clinic, and ultimately, home environments.

It needs to establish a very complex and complete human-robot relationship. Robots must be endowed with human-oriented interaction skills and capabilities, exhibit context and user-appropriate social behavior, and focus attention and communication on the user in order to help the user achieve specific goals. Different systems developed in lab research that integrates social elements and systems to form therapeutic programs that monitor, encourage, and assist users.

Stroke rehabilitation has traditionally relied on simple training equipment dedicated for a particular purpose. The advance of computing and robotics techniques provides a chance to improve on several aspects of stroke rehabilitation. Computer control can allow therapies to be customized to the individual need. Systems can be designed to be available when ever needed by the patient.

It may be possible to provide home based systems that can continue to give regular therapy sessions once the patient is discharged from hospitals. Providing intelligent therapy assistance means that there may be a chance to make objective recordings of the therapy session for subsequent analysis. In this process the traditional task of the neuro-rehabilitation specialists changes to mimic the advances brought by video analysis of games typical of professional sporting teams (particularly the teams that win).

The iRobot ConnectR is a way to stay connected to family and friends even when apart. ConnectR is used in pilot programs initially. ConnectR robots are available directly from iRobot as part of a pilot program. ConnectR Pilot Program costs are $199, afterward the product sells for $500. These markets will grow slowly, security applications are most likely to represent early adopter users.

Worldwide robotically-assisted surgery systems equipment shipment markets are set to have rapid growth. Markets at $626.5 million in 2007 are anticipated to reach $1 billion in 2008 and are forecast to go to $14 billion by 2014. Growth comes because the technology is mature and the technology works. It took a long, long time for the markets to evolve, but now the MIS surgeries are accurate and less invasive that alternative surgical methods, creating market opportunity.

A plethora of healthcare robotics markets are emerging including remote presence, security, visiting robots, services robots, and pharmaceutical robots. Robots are different from stationary devices because they have a microprocessor which can be programmed and they can move around. They have sensors.

For more information, kindly visit :
http://www.aarkstore.com/reports/Surgical-Assist-Campus-Personal-Services-and-Pharmaceutical-Robot-Market-Shares-Market-Strategies-and-Market-Forecasts-2008-2014-12048.html

Aarkstore Enterprise
Navi Mumbai, Maharashtra, India
Ph : +919272852585
Fax : +912224169996
Email : press@aarkstore.com

Indian Vaccines Industry By Aarkstore Enterprise

Vaccine manufacturers from all over the world have been involved in a stalemate with governments regarding supply and demand. While governments are reluctant to ensure steady demand for vaccines unless the manufacturers can prove their ability to increase their supply, the latter are apprehensive about increasing production without a guarantee of sustained demand from the governments. Meanwhile, developing nations are increasingly demanding vaccines that are no longer included in the immunization schedules of developed countries. These vaccines will have to be provided at very low costs, which will not be feasible unless the demand can compensate for the low margins. Global vaccines market is estimated at USD10 billion in 2007; human vaccine valued at USD8.3 billion contributes major share ie 83% of the total market and rest 17% is occupied by animal vaccine valued at USD1.7 billion. The US is the leading market, accounting for more than 50% of the global vaccine market. Influenza vaccine is the fastest growing in the adult vaccine segment followed by Hepatitis vaccines.The vaccines market in India in 2006-07 was INR30.53 billion registering a 30.41% growth over the previous year. India’s huge population makes it among the world’s largest market for vaccines of all types. India faces a growing demand for new generation and ‘combination’ vaccines, such as DPT with Hepatitis B, Hepatitis A and Injectable polio vaccine, besides several veterinary and poultry vaccines. Indian vaccines market is dominated by paediatric vaccine with 60% of market share. Combination vaccines are driving the growth of vaccine market in India.

‘Industry Insight – Vaccines’ report is prepared keeping in mind the current growth in demand for vaccines in India.The report attempts to cover the industry with a perspective of global vaccines market, segments and its growth in demand.

A market assessment of vaccines segment with reference to the market size and market trend is presented.

Vaccines report presents the growth drivers such as increasing population, disease awareness etc.

It presents the issues and challenges involved in vaccines with reference to vaccine funding, timely regulatory clearance.

It provides information on the critical success factors such as pricing, government programmes etc

10 Major players have been profiled providing introduction, financial, operational details of the company.

The report presents a brief outlook about the regulatory issues and also the regulatory aspects involved in vaccines segment.

The report provides a future outlook of vaccines market.

For more information, kindly visit :
http://www.aarkstore.com/reports/Indian-Vaccines-Industry-12555.html

Prefeasibility Report on Multi Speciality Hospital By Aarkstore Enterprise

The growth in the healthcare services in the country is driven by the 350 million strong middle class people aspiring for quality healthcare services, thus increasing international confidence on India as a potential, high quality and low cost medical tourism destination. According to the WHO report, India needs to add 80,000 hospital beds each year for the next five years to meet the demands of its growing population. High quality talent pool, proven track record, favourable government policies, ability to deliver healthcare services at low cost and high quality infrastructure has put India on the global map for outsourcing various healthcare related services.

Providing you with:

Overview of healthcare market

Insight into the procedure for setting up hospital

Industry Structure & Segmentation

Requirement of Floor space, Machinery & utility

Manpower Requirement

Capital Outlay

Financing

Profit & Loss calculation

Ratio Analysis etc

Reasons to Buy

Understand the healthcare industry

Gain a thorough understanding about the steps involved in setting up a hospital

Reveal management & commercial plans required.

Understand the major parameters involved in financial estimate

For more information, kindly visit :
http://www.aarkstore.com/reports/Prefeasibility-Report-on-Multi-Speciality-Hospital-12536.html

Pharma Industry Statistics By Aarkstore Enterprise

It has attempted to capture vital industry statistics and release such data for the benefit of industries. Given the significant export potential of Indian pharma industry, Cygnus INDSTAT (Pharma) has been prepared with an objective of providing hands on data support to the industry.

The data is provided in excel sheet form which will help the user in further estimation and analyse the industry more efficiently

Presents information on country wise pharma export and import data

It provides therapeutic segment-wise export and import data

It presents product-wise trends in exports and total export-import data over a period of time

It provides insight towards Indian Pharma Industry export scenario and further helpful in analysis

It provides 5 years of export data in Pharma Industry

For more information, kindly visit :
http://www.aarkstore.com/reports/Pharma-Industry-Statistics-12527.html

Hospital Business Management By Aarkstore Enterprise

Hospitals play a major role in the society as they provide healthcare services to patients.Increasing population and healthcare requirements and the complexity of diseases brought about radical changes in the concept of healthcare services in the country. Public healthcare system alone was unable to do justice in such a scenario. Healthcare services witnessed a tremendous growth with the entry of private multi-speciality hospitals. More and more hospitals were built to bridge the gap between demand and supply of healthcare services in a growing economy. As management of hospitals became a core issue, the demand for trained and efficient staff increased.

Key Findings & Highlights

In the present scenario, management of healthcare services has become a big challenge for corporate hospitals.

In late 1980s, Apollo Hospital was the only private hospital for profits started in Chennai.

In multi-speciality hospitals, medical specialty like general medicine, surgery, pathology,paediatrics, orthopaedics, ophthalmic, ENT, dermatology, cardiology, neurology, oncology, gastroenterology and others like endocrinology, Pulmonology & nephrology are covered.

Constraint Management is a process methodology that is especially useful for planning, organising, evaluating and controlling complex systems in an organisation.

Emergency and trauma services consists of specialists’ team from Anaesthesiology, Cardiology, Cardio-Thoracic Surgery, Gastroenterology, Internal Medicine, Neurology, Neurosurgery, Orthopaedics, Plastic Surgery, and Traumatology.

Reasons to Buy

Covers concepts of production management in a pharma company, marketing and its distribution channels, inventory management and its importance, and above all, environment management, which is critical to any pharma company

Provides insight into the key concepts of pharma business management in a comprehensive manner

Prepares students and budding management executives to face the industry confidently

For more information, kindly visit :
http://www.aarkstore.com/reports/Hospital-Business-Management-12210.html